New insider activity at Zomedica ( (ZOMDF) ) has taken place on March 19, 2025.
In a significant show of confidence in Zomedica, several top executives have made substantial purchases of the company’s stock. EVP Operations Jeffrey Rowe led the charge by acquiring 1,439,005 shares valued at $87,736. EVP Johnny Powers followed suit with a purchase of 500,000 shares for $30,500. CEO Larry C. II Heaton also bought 500,000 shares, spending $28,711. Additionally, COO Anthony K. Blair acquired 500,000 shares for $30,000, and Sr VP of Sales Klass Russell Kevin purchased 699,980 shares worth $48,998. These transactions underscore the leadership’s strong belief in Zomedica’s future prospects.
Recent Updates on ZOMDF stock
Zomedica’s recent developments highlight a mixed financial landscape. The company reported record quarterly revenue of $7.9 million and a full-year revenue of $27.3 million for 2024, driven by strong performance in its diagnostics segment and international expansion efforts. However, these achievements are tempered by challenges such as a significant net loss increase to $47 million, a delisting from the NYSE due to not meeting share price requirements, and a declining share price which has fallen below $0.20. Despite these hurdles, Zomedica maintains a strong liquidity position with $71 million and no debt, which supports its growth initiatives. The company’s strategic focus on new product launches and international market expansion is expected to drive future growth, although investor confidence may be impacted by the recent delisting and financial losses.
More about Zomedica
YTD Price Performance: -52.86%
Average Trading Volume: 8,833,374
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $49.05M